The study found that mifepristone treatment significantly reduced serum CA125 and PRL levels, and the 20 mg/kg/day dose was most effective in improving pregnancy outcomes. These findings suggest that mifepristone can reduce key biomarkers associated with uterine adenomyosis and improve fertility outcomes, offering a promising treatment option for women suffering from this condition.

Current treatment involves surgery, radiotherapy and chemotherapy (temozolomide), but survival rates remain low. Repurposing mifepristone (MF), a contraceptive drug, shows promise for GB treatment, warranting further study...The pilot trial demonstrated the pharmacological safety of using MF as an adjuvant in GB treatment. Patients treated with MF showed a significant increase in survival, with an 80% survival rate at 1 year compared to 0% in those who were treated with the standard treatment.

P2, N=24, Terminated, University of Chicago | N=74 --> 24 | Active, not recruiting --> Terminated; side effects (rash)

The likelihood of this type of response occurring by chance is extremely low. It is hoped that this report will encourage oncologists, scientists, and clinicians to further investigate the use of SPRMs in a larger cohort of patients with stage IV lung cancer, and potentially in those with less advanced disease.

PGCCs contributed to alisertib insensitivity in TNBCs that may be targeted by mifepristone.

P=N/A, N=108, Not yet recruiting, Affiliated Hospital of Nantong University; Affiliated Hospital of Nantong University

The expression levels of GR and FOXO1 or p-FOXO1 were strongly correlated in bladder cancer. Specific GR/FOXO1 and GR/p-FOXO1 expression profiles served as independent predictors of disease recurrence or progression.

In brief, our study demonstrates that stress-corticosterone axis induces exhaustion of tumor-infiltrating CD8+ T cells, contributing to accelerated progression of non-small cell lung cancer.

Monitoring of estradiol(E2) levels before the management is recommended. Risk assessment and preventive strategies, such as intermittent treatment, transvaginal ultrasound and levonorgestrel intrauterine system (LNG-IUS), should be considered.

P4, N=1900, Not yet recruiting, Ibis Reproductive Health

P3, N=1186, Recruiting, Leiden University Medical Center | Not yet recruiting --> Recruiting

P2, N=400, Recruiting, Chelsea and Westminster NHS Foundation Trust | Trial primary completion date: Oct 2025 --> Dec 2026